Bayer HealthCare Pharmaceuticals
340 Changebridge RoadPine Brook, New Jersey 07
Phone: 973-487-2000800 Dwight Way
Berkeley
California
94701
United States
Tel: 510-705-5000
Fax: 510-705-7878
Website: http://www.bayerjobs.com/
111 articles about Bayer HealthCare Pharmaceuticals
-
Bayer HealthCare Pharmaceuticals Submits New Drug Application For LCS-16 For Pregnancy Prevention For Up To Five Years
11/20/2015
-
Bayer HealthCare Pharmaceuticals Presents New Data On BETASERON (interferon beta-1b) At ECTRIMS 2015
10/9/2015
-
Bayer HealthCare Pharmaceuticals To Bring Prostate Cancer Awareness To Center Court With Coaches Vs. Cancer Partnership
8/24/2015
-
Bayer HealthCare Pharmaceuticals To Present New Data On Copanlisib In Hematological Malignancies
6/17/2015
-
Afaxys And Bayer HealthCare Pharmaceuticals Form Alliance To Expand Access To Contraception In The Public Health Sector
6/8/2015
-
Bayer HealthCare Pharmaceuticals Release: Survey Shows Most Men With Advanced Prostate Cancer Ignore Their Symptoms As Disease Progresses[1]
6/1/2015
-
Bayer HealthCare Pharmaceuticals Has Selected Biologics, Inc. (NC) As A Limited Distribution Network Provider For NEXAVAR (Sorafenib) And STIVARGA (Regorafenib)
2/23/2015
-
ESMO 2014 To Feature New Oncology Data From Across Bayer HealthCare Pharmaceuticals Franchise
9/24/2014
-
Bayer HealthCare Pharmaceuticals And Orion Corporation Initiate Phase 3 Trial Of ODM-201 In Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
9/16/2014
-
Bayer HealthCare Pharmaceuticals May Add 80,000-Square-Foot Product-Testing Facility In Berkeley, California
8/29/2014
-
Dieter Weinand Tapped To Be President Of Bayer HealthCare Pharmaceuticals
6/6/2014
-
Bayer HealthCare Pharmaceuticals Introduces New Bayer Inserter For Mirena® (Levonorgestrel-Releasing Intrauterine System) 52 Mg
6/2/2014
-
Bayer HealthCare Pharmaceuticals Release: Phase 3 DECISION Trial Of NEXAVAR (Sorafenib) In Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory To Radioactive Iodine Published In The Lancet
4/24/2014
-
Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc.'s Nexavar Misses Target In Phase 3 Liver Cancer Trial
3/11/2014
-
Bayer HealthCare Pharmaceuticals' Long-Acting Hemophilia Drug Shown To Be Effective
2/18/2014
-
Bayer HealthCare Pharmaceuticals to Present Data Investigating Recently Approved Adempas® (riociguat) Tablets
10/28/2013
-
FDA Approves Bayer HealthCare Pharmaceuticals's New Class of Drug Adempas® (riociguat) Tablets to Treat Adults With PAH and Persistent, Recurrent or Inoperable CTEPH
10/9/2013
-
FDA Advisory Panel Backs Bayer HealthCare Pharmaceuticals's Riociguat for Lung Disease
8/7/2013
-
Bayer HealthCare Pharmaceuticals Release: The New England Journal of Medicine Publishes Results From the Phase III ALSYMPCA Study of Xofigo® (Radium Ra 223 Dichloride) Injection
7/18/2013
-
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. Announce Submission of FDA and European Medicines Agency Applications for Nexavar® (sorafenib) for the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer
7/1/2013